Selling to Hospitals vs Specialty Practices vs Payers: Which Provider Channel a Series A Should Test First

This is the question I am least confident giving a clean answer to. I have been wrong on it twice, both times advising companies I worked with directly. Both times I underweighted how operationally demanding the channel choice was for the team they actually had.

So consider this an honest framework rather than a recommendation. The decision about which provider channel to lead with is structurally similar to product positioning. It constrains everything downstream. The cost of changing course later is high. Unlike product positioning, which most founders agonize over, channel selection often gets made by default rather than by analysis. Either the company sells to whichever channel the founder has personal relationships in, which is fine but accidental. Or the company tries to sell into all three at once, which almost never works at Series A scale because each channel requires a different sales motion, a different rep profile, a different contract structure, and a different proof point set.

What follows is my best attempt at an honest read on each channel. I will mark the parts I am less certain about.

The three channels at a glance

These ranges are approximations. Specialty practice contracts at $400K and payer contracts at $150K both exist out there. The rough shape holds across most provider-facing health-tech companies I have observed, but every individual deal will look like an exception to the table.

What you are signing up for with each channel

The headline numbers do not capture the work.

A hospital sale at Series A is typically a multi-stakeholder process. You will spend three to six months building consensus across a service-line owner, a clinical champion, an IT or security reviewer, and a finance or supply chain stakeholder. The contract value is substantial, but the operational requirement is also substantial. You need a senior enterprise rep who can navigate hospital decision-making structures. You need product certifications (HIPAA at minimum, often HITRUST or SOC 2 Type II). You need legal capacity to work through hospital contract templates. A Series A health-tech that lands two health system contracts in year one has a strong story. A Series A health-tech that spends nine months chasing one health system contract that does not close has a runway problem.

Specialty practice sales are usually faster and smaller. Buyer concentration is more diffuse, which means you need more total opportunities to hit the same revenue, but each opportunity moves faster. The rep profile is different too. Where hospital sales reward enterprise consultative selling, specialty practice sales reward relationship-driven territory coverage. The reps who succeed in specialty practice sales often have ten or fifteen years calling on a specific specialty, with relationships that get them into administrator offices that a stranger would not access. This is the channel where the contract field rep model fits most naturally.

Payer sales are the longest and largest. They are also the most operationally demanding. Payer contracts often include performance guarantees, which means you are not just selling the product, you are committing to outcomes the payer will measure. The buying committee is bigger and slower than a hospital's, and the contract negotiation phase alone can run six to twelve months. A Series A health-tech taking on a payer-led GTM is making a structural commitment that will eat most of the round. It is the right call sometimes, but I would push back hard on it as a default.

The runway implications

I am going to put numbers next to each channel choice, but I want to flag upfront that these have wider variance than the table makes it look.

The "first contract" timing assumes a competent rep working a defined territory. It does not assume founder-led sales, which can sometimes move faster on the first contract because the founder has unique credibility with early buyers. But founder-led sales does not scale into the second, third, and fourth contract.

There are Series A health-techs that survive a hospital-first GTM. It usually requires a longer runway than typical Series A, an unusually fast-moving pilot health system, or a willingness to take the company sub-scale and raise a smaller bridge. None of those are reliable.

The wedge constrains the universe

The channel choice is constrained by what the product actually does, which sometimes makes the whole question moot.

A clinical decision support tool for cardiologists has to sell to specialty cardiology practices or to health systems with cardiology service lines. A population health analytics tool has to sell to payers or to risk-bearing health systems. The product determines the universe of viable channels. Within that universe, the choice is usually: do we go to the smaller buyer where the sales cycle is faster, or do we go to the larger buyer where the contract is bigger?

Series A health-techs systematically underweight the value of fast pipeline data and overweight the value of large contract size. As a result they default to channels that are too slow for their runway. I am fairly confident this is true. I am less confident I have a clean way to tell when it is the wrong instinct.

There is also a buyer-readiness question that often gets ignored. Some products are operationally ready for hospital sales, meaning the security posture, the contracting templates, the implementation playbook, and the customer success motion can all support a $500K hospital deployment. Other products are not, even if the product itself is technically capable. A Series A company without HITRUST certification trying to sell to large IDNs is going to spend six months in security review and lose the deal.

The hybrid case

The most interesting pattern at Series A health-techs is the deliberate hybrid: lead with specialty practices to generate pipeline velocity and reference customers, then layer hospital sales on top once the specialty practice motion is proven. The specialty practice contracts produce revenue and reference accounts in the first six to nine months. Those reference accounts become the credibility that opens hospital conversations later.

The reason this sequencing works is that specialty practices buy faster, give you reference accounts, and produce pipeline data that informs hospital messaging. Hospitals tend not to be early adopters at Series A scale. They are easier to land once you have specialty practice traction to point to.

Where this gets harder than I made it sound

A few places the framework above breaks down, in my experience.

The hybrid sequence assumes the product genuinely fits both channels. Many products sit in an awkward middle where they are not quite right for specialty practices (workflow too clinical, requires IT integration that small practices do not have) and not quite right for hospitals yet (security posture not ready, customer success team too small). For those companies, the answer is usually to stay in one channel until the product matures, but founders rarely want to hear that.

The "specialty practices first" path assumes you have buyers in those practices who will adopt without insurance reimbursement clarity. For some products, the value prop only works if the practice can bill for it. If reimbursement is unsettled, specialty practices will pilot but not commit. I have seen this stall companies for nine to twelve months because the team kept trying to close practices that structurally could not commit until reimbursement was clearer.

The contract size ranges in the table at the top of this article are pre-discount. Real contracts close at 60-80% of the listed list price more often than I would like, especially at Series A when the company has not yet established pricing power. The runway math gets tighter than the table suggests.

The "hospital sale" category is actually two categories: academic medical centers and community health systems. Academic centers are slower, more research-oriented, more likely to want pilots and publications. Community systems are faster on commercial decisions but more conservative on technical risk. The table treats them as one category. They are not one category.

There are probably more places this framework is too neat. If a VP of Commercial reading this disagrees with the framing on their own company, the disagreement is probably correct. The data they have on their own product, market, and team beats anything I can offer at this level of generality.

A sequence for the first ninety days

The compressed version, for a VP of Commercial in their first thirty days.

Start by inventorying the founder's existing customer base. Which channel did the existing contracts come from? Are any of them stuck in negotiation? Where is the founder spending most of their relationship time? That is your starting position, regardless of where you eventually want to be.

Then audit operational readiness. What channels can the product actually be sold into today, given current security posture, contracting templates, implementation capacity, and customer success staffing? Some channels may be off the table for nine to twelve months regardless of strategy. (The hospitals piece covers what hospital readiness actually looks like in more detail.)

Then run a small market test in the most viable channel. Contract reps fit naturally here, because they let you test channel viability without committing to a W2 hire for a channel that may not work. The mechanics of that test are a separate piece, but the short version is: 90 days, defined activity quota, written recommendation at day 91.

Evaluate the results. Commit to a primary channel. Start building the team for it. The W2 hires that come after this point are informed by data the contract reps produced, not by hypothesis alone.

This is faster than most Series A health-techs run this decision. I think it is structurally correct because the cost of being wrong on channel selection is high enough that you should not commit to it before you have tested. But I will admit the speed is partly driven by Series A runway pressure, not by any belief that fast decisions are inherently better than careful ones. A company with a longer runway could afford to take this slower. Most of the ones I work with do not have that luxury.